The Efficacy of PD-1 Antibody Sintilimab on Early-stage Multiple Primary Lung Cancer With Ground Glass Density.
A single-center,prospective interventional study to explore the efficacy of PD-1 antibody Sintilimab on early-stage multiple primary lung cancer patients with ground-glass nodules in CT scan.
Multiple Primary Lung Cancers
DRUG: PD-1 antibody Sintilimab
ORR of target lesions., The objective response rate will be evaluated after 4 courses of treatment, 3 months
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0, The safty of PD-1 Antibody Sintilimab, 3 months
This study is a single-center,prospective interventional clinical study, all subjects enrolled are multiple primary lung cancer patients with ground-glass density in CT scan.The samples plan for the study was 36 cases.The enrolled patients will receive intravenous infusion of Sintilimab 200mg every 3 weeks up to 4 cycles, and the efficacy will be evaluated after cycle 2 and 4 using RECIST criteria (version 1.1 ).